Showing results (211-220 of 313) with videos related to
Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinFarhad Ravandi, Eli Estey, Dan Jones, et al.Blood|August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.Investigational New Drugs|June 10, 2010
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cellsWei-Gang Tong, Zeev Estrov, Yongtao Wang, et al.Blood Advances|May 13, 2020
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromeJe-Hwan Lee, Stefan Faderl, John M Pagel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemiaFrancis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.Blood|January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderStefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.Clinical Lymphoma, Myeloma & Leukemia|April 27, 2012
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemiaElias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.Pageof 32